Browsing category:

Anti-Fungal


Exciting news was shared in the January 2015 issue of Mycoses, with clinical data revealing that the use of Caspofungin to treat invasive fungal disease in leukemia patients was both positive and responsive. Adult patients who were diagnosed with acute lymphoblastic leukemia attained relief from their suspected fungal disease after the clinical use of Caspofungin.[…]

Read More

As the fourth most common cause of hospital-acquired bloodstream infections in the United States, Invasive Candidiasis is a concern for any patient battling a fungal infection. Micafungin, also known as the brand name Mycamine, which is marketed by Astellas, is an effective antifungal agent. By inhibiting the synthesis of 1,3-beta-D-glucan, Micafungin proves to be a[…]

Read More

Anacor Pharmaceuticals, Inc. ANAC, announced on Jul 08, 2014 that the FDA has approved the New Drug Application for Tavaborole, which is marketed as KERYDIN™ topical solution, 5%. Tavaborole was designed to be convenient for patients to use and it’s the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis[…]

Read More

Butoconazole Nitrate, CAS number 64872-77-1 is also known as the brand name GYNAZOLE-1. Marketed by Ther-Rx Corporation, the patent for this vaginal cream expires November 17, 2017. Indicated for the treatment of vulvovaginal candidiasis, or infections caused by Candida, butoconazole is available in a 2% strength cream. Statistically Candida, or yeast infections, are extremely common.[…]

Read More

Itraconazole is an azole antifungal medicine. Known as the brand name Sporanox, which is marketed Janssen, the patent for this potent product expires on January 13, 2015. Itraconazole works by interfering with the formation of the fungal cell membrane. It is a formidable product for treating infections caused by fungus, which can invade any part[…]

Read More

Amphotericin B is also known as the brand name Ambisone. With Astellas Pharma’s patent for Ambisome due to expire on February 23, 2016, this injectable medication for deadly fungal infections is geared up for attention in the pharmaceutical community. More than 6 billion dollars is spent worldwide on anti-fungal medications, and the total costs of[…]

Read More

Voriconazole is also known as the brand name Vfend, which is marketed by Pfizer. As an antifungal medication, voriconazole is typically reserved for treating patients with serious fungal infections, like invasive aspergillosis. Voriconazole is a formidable opponent for fungal infections that begin in the lungs and spread through the bloodstream to other organs, like invasive[…]

Read More